-
Founded in:
1997-08-13 -
Country:
China -
Address:
No. 63, Kexin Road, Jiangbei New District, Nanjing -
Tax NO.:
91320100634081762H -
Registered Funds:
$46.83 million -
Website:
-
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| LEVOFLOXACIN LACTATE |
Unspecified
More
Unspecified |
294662-18-3 | 11 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| LEVOFLOXACIN LACTATE |
Antibacterial effect
More
Antibacterial effect |
294662-18-3 | 11 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Pantoprazole Sodium |
This product is a proton pump inhibitor of gastric parietal cells. It can specifically inhibit the secretory microtubules and tubular vesicles in the cytoplasm of the parietal cell apical membrane, causing irreversible inhibition of the enzyme, thereby effectively inhibiting the secretion of gastric acid. It can not only non-competitively inhibit the gastric acid secretion caused by gastrin, histamine, and choline, but also inhibit some basic gastric acid secretion that is not affected by choline or H2 receptor blockers. This product is metabolized through the first system of the cytochrome P450 enzyme system in liver cells, and can also be metabolized through the second system, reducing the interaction between drugs in the body. It has no mutagenic, carcinogenic and teratogenic effects.
More
This product is a proton pump inhibitor of gastric parietal cells. It can specifically inhibit the secretory microtubules and tubular vesicles in the cytoplasm of the parietal cell apical membrane, causing irreversible inhibition of the enzyme, thereby effectively inhibiting the secretion of gastric acid. It can not only non-competitively inhibit the gastric acid secretion caused by gastrin, histamine, and choline, but also inhibit some basic gastric acid secretion that is not affected by choline or H2 receptor blockers. This product is metabolized through the first system of the cytochrome P450 enzyme system in liver cells, and can also be metabolized through the second system, reducing the interaction between drugs in the body. It has no mutagenic, carcinogenic and teratogenic effects. |
138786-67-1 | 57 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Rabeprazole Sodium |
Extract from the above information
More
Extract from the above information |
117976-90-6 | 53 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Liranaftate |
Extract from the above information
More
Extract from the above information |
88678-31-3 | 11 |